NASP

Articles

More targeted therapies often have better toxicity profiles, allowing patients to remain adherent for longer.

Recent Developments in Therapeutics for GIST, Non-Small Cell Lung Cancer

Recent studies have analyzed how individuals with autoimmune conditions prescribed specialty medications may be affected by the COVID-19 pandemic.

COVID-19 Studies Show Impact to Certain Patients With Autoimmune Conditions

Digital health tools were a major theme during the first-ever NASP Challenge, comprising 4 of the 5 finalists.
 

Digital Tools for Respiratory Disease Win First Ever NASP Challenge

There were a number of FDA approvals in 2019 that were either the first new therapies or first in class approved for certain conditions, and the specialty pipeline is continuing to grow at a rapid pace.

Specialty Drug Pipeline Poised to Offer Many New Therapies in the Coming Year

Technology can help revolutionize how a pharmacy manages patients, collects payments, communicates, and can improve overall efficiency.

Integrating New Technology into Pharmacy Operations

Clinical education, strong data analytics, and valuing collaboration are the best ways to provide patient support and access to specialty pharmaceutical manufacturers.

What to Expect from a Specialty Pharmacy Partner

Protections for covered entities under the 340B program will most likely be affected by decisions in the Senate.

Regulatory and Legislative Actions Currently Impacting the 340B Program

The COVID-19 pandemic has contributed to specialty pharmacy outpacing traditional pharmacy in non-discounted spending.

Specialty Pharmacy Outpaces Traditional Pharmacy Growth

Data standardization has been an ongoing problem in the specialty pharmacy field, affecting both patients and providers when approaching treatments.

The Path Ahead for Data Standardization in Specialty Pharmacy

During the COVID-19 pandemic, many families and individuals have not been able to pay their out-of-pocket costs or do not have enough money saved to pay their deductibles.